- Home
- FC vs TVRD Comparison
FC vs TVRD Comparison
Compare FC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FC
- TVRD
- Stock Information
- Founded
- FC 1983
- TVRD 2017
- Country
- FC United States
- TVRD United States
- Employees
- FC N/A
- TVRD N/A
- Industry
- FC Other Consumer Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- FC Consumer Discretionary
- TVRD Health Care
- Exchange
- FC Nasdaq
- TVRD Nasdaq
- Market Cap
- FC 239.1M
- TVRD 246.5M
- IPO Year
- FC 1992
- TVRD N/A
- Fundamental
- Price
- FC $19.10
- TVRD $30.63
- Analyst Decision
- FC Strong Buy
- TVRD Strong Buy
- Analyst Count
- FC 2
- TVRD 5
- Target Price
- FC $27.00
- TVRD $59.20
- AVG Volume (30 Days)
- FC 149.0K
- TVRD 20.2K
- Earning Date
- FC 11-05-2025
- TVRD 08-14-2025
- Dividend Yield
- FC N/A
- TVRD N/A
- EPS Growth
- FC N/A
- TVRD N/A
- EPS
- FC 0.81
- TVRD N/A
- Revenue
- FC $279,943,000.00
- TVRD N/A
- Revenue This Year
- FC N/A
- TVRD N/A
- Revenue Next Year
- FC $1.23
- TVRD N/A
- P/E Ratio
- FC $23.77
- TVRD N/A
- Revenue Growth
- FC N/A
- TVRD N/A
- 52 Week Low
- FC $18.32
- TVRD $8.13
- 52 Week High
- FC $44.16
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- FC 45.07
- TVRD 65.37
- Support Level
- FC $18.69
- TVRD $28.20
- Resistance Level
- FC $19.67
- TVRD $31.88
- Average True Range (ATR)
- FC 0.68
- TVRD 1.76
- MACD
- FC 0.03
- TVRD 0.32
- Stochastic Oscillator
- FC 28.48
- TVRD 87.63
About FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.